Clinical Trial Update: A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma [Phase 2]

View source ↗

Summary

A Phase II clinical trial update describes evaluating the addition of N-803 to a chemoimmunotherapy backbone for relapsed or refractory neuroblastoma; the study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• N-803

Snippet

Sponsor: St. Jude Children's Research Hospital | Conditions: Neuroblastoma Recurrent | Phase 2 | Status: RECRUITING